Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia

NCT03426605 is registered in ClinicalTrials.gov with OrphAI Therapeutics as lead sponsor.

NCT NCT03426605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03426605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Lead sponsor
OrphAI Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 16, 2018
Completion date
October 5, 2020
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, oncology